References
- Cost–Effectiveness in Health and Medicine. Gold MR, Siegel JE, Russell LB, Weinstein MC (Eds). Oxford University Press, NY, USA (1996).
- Neumann PJ. Using Cost–Effectiveness Analysis to Improve Health Care. Oxford University Press, NY, USA (2005).
- Siegel JE. Cost–effectiveness analysis in US healthcare decision-making: where is it going? Med. Care 43(7), 1–4 (2005).
- Drummond M, Sculpher M. Common methodological flaws in economic evaluation. Med. Care 43(7), 5–14 (2005).
- Laupacis A. Incorporating economic evaluations into decision-making: the Ontario experience. Med. Care 43(7), 15–19 (2005).
- Aspinall SL, Good CB, Glassman PA et al. The evolving use of cost-effectiveness analysis in formulary management within the Department of Veterans Affairs. Med. Care 43(7), 20–26 (2005).
- Neumann PJ. The arrival of economic evidence in managed care formulary decisions: the unsolicited request process. Med. Care 43(7), 27–32 (2005).
- Helfand M. Incorporating information about cost-effectiveness into evidence-based decision-making: the evidence-based practice center (EPC) model. Med. Care 43(7), 33–42 (2005).
- Luce BR. What will it take to make cost–effectiveness analysis acceptable in the United States? Med. Care 43(7), 44–48 (2005).
- Berger ML, Teutsch S. Cost–effectiveness analysis: from science to application. Med. Care 43(7), 49–53 (2005).
- Garber AM. Evidence-based guidelines as a foundation for performance incentives. Health Aff. (Millwood) 24(1), 174–179 (2004).
- Garber AM. Cost–effectiveness and evidence evaluation as criteria for coverage policy. Health Aff. (Millwood) 284–296 (2004).
- Neumann PJ. Evidence-based and value-based formulary guidelines. Health Aff. (Millwood) 23(1), 124–134 (2004).
- Mauskopf JA, Paul JE, Grant DM et al. The role of cost-consequence analysis in healthcare decision-making. Pharmacoeconomics13(3), 277–288 (1998).
- Singer SJ, Bergthold LA. Prospects for improved decision making about medical necessity. Health Aff. (Millwood) 20(1), 200–206 (2001).
- Tunis SR. Economic analysis in healthcare decisions. Am J. Manag. Care 10(5), 301–304 (2004).
- Neumann PJ. Why don’t Americans use cost–effectiveness analysis? Am J. Manag. Care 10(5), 308–312 (2004).
- Ginsburg ME. Cost–effectiveness: will the public buy it or balk? Health Aff. (Millwood) W4-297–W4-299 (2004).
- Prosser LA, Koplan JP, Neumann PJ et al. Barriers to using cost–effectiveness analysis in managed care decision making. Am. J. Manag. Care 6(2), 173–179, 1999.
- Langley PC. Is cost–effectiveness modeling useful? Am J. Manag. Care 6(2), 250–251 (2000).
- Neumann PJ, Rosen AB, Weinstein MC. Medicare and cost–effectiveness analysis. N. Engl. J. Med. 353(14), 1516–1522 (2005).
- Meenan RT, Fleming C, Whitlock EP et al. Evidence synthesis of cost–effectiveness analyses of population screening for abdominal aortic aneurysm. Evidence report. Agency for Healthcare Research and Quality, Rockville, MD, USA (2004).
- Meenan RT, Saha S, Chou R et al. Effectiveness and cost–effectiveness of echocardiography and carotid imaging in the management of stroke. Evidence report. Agency for Healthcare Research and Quality, Rockville, MD, USA (2002).
- Meenan RT, Stevens VJ, Hornbrook MC et al. Cost–effectiveness of a hospital-based smoking-cessation intervention. Med. Care 36(5), 670–678 (1998).
- Lynch FL, Hornbrook M, Clarke GN et al. Cost–effectiveness of an intervention to prevent depression in at-risk teens. Arch. Gen. Psychiatry 62(11), 1241–1248 (2005).
- Lynch FL, Whitlock EP, Valanis BG et al. Cost–effectiveness of a tailored intervention to increase screening in HMO women overdue for Pap test and mammography services. Prev. Med. 38(4), 403–411 (2004).
- Smith DH, Fenn P, Drummond M. Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case. Br. J. Ophthalmol. 88(9), 1107–1112 (2004).
- Bonomi AE, Boudreau DM, Fishman PA et al. Is a family equal to the sum of its parts? Estimating family-level well-being for cost–effectiveness analysis. Qual. Life Res. 14(4), 1127–1133 (2005).
- Coffield AB, Maciosek MV, McGinnis JM et al. Priorities among recommended clinical preventive services. Am. J. Prev. Med. 21(1), 1–9 (2001).
- Maciosek MV, Coffield AB, McGinnis JM et al. Methods for priority setting among clinical preventive services. Am. J. Prev. Med. 21(1), 10–19 (2001).
- Carande-Kulis VG, Maciosek MV, Briss PA et al. Methods for systematic reviews of economic evaluations for the Guide to Community Preventive Services. Task Force on Community Preventive Services. Am. J. Prev. Med. 18(Suppl. 1), 75–91 (2000).
- Morlock RJ, Lafata JE, Eisenstein D. Cost–effectiveness of single-dose methotrexate compared with laparoscopic treatment of ectopic pregnancy. Obstet. Gynecol. 95(3), 407–412 (2000).
- Lafata JE, Martin SA, Kaatz S et al. Anticoagulation clinics and patient self-testing for patients on chronic warfarin therapy: a cost–effectiveness analysis. J. Thromb. Thrombolysis. 9(Suppl. 1), S13–S19 (2000).
- Schoenbaum M, Sherbourne C, Wells K. Gender patterns in cost effectiveness of quality improvement for depression: results of a randomized, controlled trial. J. Affect. Disord. 87(2–3), 319–325 (2005).
- Benner JS, Smith TW, Klingman D et al. Cost–effectiveness of rosuvastatin compared with other statins from a managed care perspective. Value Health 8(6), 618–628 (2005).
- Alegria M, Frank R, McGuire T. Managed care and systems cost–effectiveness: treatment for depression. Med. Care 43(12), 1225–1233 (2005).
- Kominski GF, Heslin KC, Morgenstern H et al. Economic evaluation of four treatments for low-back pain: results from a randomized controlled trial. Med. Care 43(5), 428–435 (2005).
- Sullivan SD, Lee TA, Blough DK et al. A multisite randomized trial of the effects of physician education and organizational change in chronic asthma care: cost-effectiveness analysis of the Pediatric Asthma Care Patient Outcomes Research Team II (PAC-PORT II). Arch. Pediatr. Adolesc. Med. 159(5), 428–434 (2005).
- Simons WR, Jones D, Buzdar A. Cost– effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer. Clin. Ther. 25(11), 2972–2987 (2003).
- Shaw E, Stacy J, Arledge MD et al. Pharmacoeconomic modeling of prior-authorization intervention for COX-2 specific inhibitors in a 3-tier copay plan. J. Manag. Care Pharm. 9(4), 327–334 (2003).
- Meenan RT, Goodman MJ, Fishman PA et al. Issues in pooling administrative data for economic evaluation. Am. J. Manag. Care 8(1), 45–53 (2002).
- Ubel PA. Pricing Life. The MIT Press, Cambridge, MA, USA (2000).
- Fry RN, Avey SG, Sullivan SD. The academy of managed care pharmacy Format for formulary submissions: an evolving standard – a foundation for Managed Care Pharmacy Task Force report. Value Health 6(5), 505–521 (2003).
- O’Brien BJ. Academy of Managed Care Pharmacy Format: relevance, rigor, regulation, and realism. Value Health 6(5), 501–502 (2003).
- Drummond M, Brown R, Fendrick AM et al. Use of pharmacoeconomics information – report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making. Value Health 6(4), 407–416 (2003).
- Mauskopf JA, Earnshaw SR, Mullins C. Budget impact analysis: review of the state of the art. Expert Rev. Pharmacoeconomics Outcomes Res. 5(1), 65–79 (2005).
- Chang J, Sung J. Health plan budget impact analysis for pimecrolimus. J. Manag. Care Pharm. 11(1), 66–73 (2005).
- Trueman P, Drummond MF, Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics19, 609–621, (2001).
- Goetzel RZ, Ozminkowski RJ, Villagra VG et al. Return on investment in disease management: a review. Health Care Finan. Rev. 26(4), 1–19 (2005).
- Bloom BS. Use of formal benefit/cost evaluations in health system decision making. Am. J. Manag. Care 10(5), 329–335 (2004).
- Leatherman S, Berwick D, Iles D et al. The business case for quality: case studies and an analysis. Health Aff. (Millwood) 22(2), 17–30 (2003).
- Ozminkowski RJ, Dunn RL, Goetzel RZ et al. A return on investment evaluation of the Citibank, NA, health management program. Am. J. Health Promot. 44(1), 31–43 (1999).
- Ozminkowski RJ, Goetzel RZ, Smith MW et al. The impact of the Citibank, NA, health management program on changes in employee health risks over time. J. Occup. Environ. Med. 42(5), 502–511 (2000).
- Goetzel RZ, Jacobson BH, Aldana SG et al. Health care costs of worksite health promotion participants and non-participants. J. Occup. Environ. Med. 40(4), 341–346 (1998).
- Sackett K, Pope RK, Erdley WS. Demonstrating a positive return on investment for a prenatal program at a managed care organization: an economic analysis. J. Perinat. Neonat. Nurs. 18(2), 117–127 (2004).
- Wilson TW, Gruen J, Thar W et al. Assessing return on investment of defined-population disease management interventions. Jt. Comm. J. Qual. Saf. 30(11), 614–621 (2004).
- Saha S, Hoerger TJ, Pignone MP et al. The art and science of incorporating cost effectiveness into evidence-based recommendations for clinical preventive services. Am. J. Prev. Med. 20(Suppl. 3), 36–43 (2001).
- Drummond MF, Sculpher MJ, Torrance GW et al. Methods for the Economic Evaluation of Health Care Programmes, (3rd Edition). Oxford University Press, NY, USA (2005).
- Meltzer D. Accounting for future costs in medical cost–effectiveness analysis. J. Health Econ. 16, 33–64 (1997).
- Meltzer D, Egleston B, Stoeffel D et al. Effect of future costs on cost-effectiveness of medical interventions among young adults: the example of intensive therapy for type 1 diabetes mellitus. Med. Care 38, 679–685 (2000).
- Johannesson M, Meltzer D, O’Conor RM. Incorporating future costs in medical cost-effectiveness analysis: implications for the cost–effectiveness of the treatment of hypertension. Med. Dec. Making17, 382–389 (1997).
- Manns B, Meltzer D, Taub K et al. Illustrating the impact of including future costs in economic evaluation: an application to end-stage renal disease care. Health Econ.12, 949–958 (2003).
Websites
- Disease Management Association of America. Definition of disease management (2005). www.dmaa.org/definition.html
- Bergthold LA, Singer SJ, Huang A et al. Using evidence and cost in managed care decision-making. Center for Health Policy/Center for Primary Care and Outcomes Research, Stanford University, Stanford, CA, USA (2002). content.healthaffairs.org/cgi/content/full/hlthaff.w4.284v1/DC2
- Blue Cross Blue Shield Association Technology Evaluation Center. http://www.bcbs.com/tec/index.html
- HMO Research Network home page. http://hmoresearchnetwork.org/home.htm
- Sacramento Healthcare Decisions. Cost-effectiveness as a criterion for medical and coverage decisions: understanding and responding to community perspectives. www.sachealthdecisions.org.vf.pdf
- International Society for Pharmacoeconomics & Outcomes Research. ISPOR budget impact analysis task force. www.ispor.org/workpaper/ budget_impact.asp
- The Health Plan Employer Data and Information Set (HEDIS®). Washington, DC, USA. National Committee for Quality Assurance. www.ncqa.org/Programs/HEDIS